TD Asset Management Inc Acquires 6,581 Shares of United Therapeutics Corporation $UTHR

TD Asset Management Inc grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 5.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 138,859 shares of the biotechnology company’s stock after purchasing an additional 6,581 shares during the quarter. TD Asset Management Inc’s holdings in United Therapeutics were worth $58,211,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of UTHR. Wilmington Savings Fund Society FSB lifted its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Abich Financial Wealth Management LLC bought a new position in United Therapeutics in the third quarter valued at about $44,000. WealthCollab LLC raised its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, True Wealth Design LLC lifted its holdings in shares of United Therapeutics by 738.5% in the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 96 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company upped their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a report on Thursday. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday. Finally, TD Cowen upped their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $533.55.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $503.60 on Friday. The stock has a market capitalization of $21.68 billion, a PE ratio of 18.05, a price-to-earnings-growth ratio of 2.85 and a beta of 0.85. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $537.19. The stock has a 50 day moving average price of $484.64 and a two-hundred day moving average price of $444.51.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same period last year, the business earned $6.19 EPS. United Therapeutics’s quarterly revenue was up 7.4% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $479.91, for a total transaction of $10,797,975.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the completion of the sale, the chief financial officer owned 8,142 shares in the company, valued at $3,908,078.58. This represents a 72.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 407,954 shares of company stock worth $197,601,528 over the last ninety days. Insiders own 10.30% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.